Nina Isoherranen

The paper shows that FABP1 affects CYP2C9-mediated drug metabolism in human liver models, improving prediction accuracy when included in physiologically based models.

This study identifies the main cytochrome P450 enzymes responsible for metabolizing Δ8-THC in human liver microsomes and shows that CYP2C9 is the primary catalyst for its 11-hydroxylation.

This study profiles membrane-associated proteins in human placenta across pregnancy trimesters, identifying changes in transporter abundance linked to gestational age.

This study develops a plasma protein binding model to predict unbound cortisol and cortisone concentrations by accounting for changes in ligand and protein concentrations across physiological states.

This study presents a comprehensive proteomic dataset of human omental and subcutaneous adipose tissue across a wide BMI range to uncover depot-specific biological changes associated with adiposity.

This study develops a liver distribution model incorporating intracellular lipid partitioning and FABP1 binding to improve Kp prediction accuracy for drugs.

This study investigates how dicloxacillin and flucloxacillin inhibit hepatic and renal transporters in vitro and uses PBPK modeling to assess clinical relevance.

This study develops and validates an LC-MS/MS method for absolute quantitation of RBP4 and TTR in serum and plasma, showing good linearity, precision, and correlation with ELISA.

This study shows drugs form ternary complexes with human FABP1 and that FABP1 binding alters drug metabolism by affecting CYP2C9 activity.

The paper predicts SARS-CoV-2 B-cell epitopes using computational methods and validates them with ELISA, finding two antigens with high sensitivity and specificity for serological diagnosis of COVID-19.